3 hours BMO Capital Markets Lowers Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $114.00MarketBeat
BMO Capital Markets decreased their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a research note on Thursday.
Markets · Nasdaq 100 · Science
X